Document is current
Any future updates will be listed below
-
Authors
Wang, Jiaming https://orcid.org/0000-0002-4834-967X
Zhang, Yue https://orcid.org/0000-0003-1144-1445
Mendonca, Craig A. https://orcid.org/0000-0001-9938-6481
Yukselen, Onur
Muneeruddin, Khaja
Ren, Lingzhi
Liang, Jialing
Zhou, Chen
Xie, Jun https://orcid.org/0000-0001-9565-1567
Li, Jia
Jiang, Zhong
Kucukural, Alper https://orcid.org/0000-0001-9983-394X
Shaffer, Scott A.
Gao, Guangping https://orcid.org/0000-0003-0097-9012
Wang, Dan https://orcid.org/0000-0001-9079-2360
- License Information
-
More Information
Article History
Received: 9 July 2021
Accepted: 5 January 2022
First Online: 23 March 2022
Change Date: 12 May 2022
Change Type: Update
Change Details: In the version of this article initially published, the name of John Leuck was not included in the Peer review information for this article, which has now been amended.
Competing interests
: J.W., Y.Z., C.A.M., G.G. and D.W. are inventors of a patent application filed by the University of Massachusetts Chan Medical School concerning the design and applications of sup-tRNAs described in this study. G.G. is a scientific co-founder of Voyager Therapeutics, Adrenas Therapeutics and Aspa Therapeutics and holds equity in these companies. G.G. and D.W. are inventors on patents related to AAV-based gene therapy, some of which were licensed to commercial entities. The other authors declare no competing interests.
